As of 2026-03-18, the Relative Valuation of Kinnate Biopharma Inc (KNTE) is (57.20) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.65 USD, the upside of Kinnate Biopharma Inc based on Relative Valuation is -2258.3%.
The range of the Relative Valuation is (52.35) - (65.67) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.9x - 28.8x | 25.2x |
| Forward P/E multiples | 21.7x - 27.5x | 22.7x |
| Fair Price | (52.35) - (65.67) | (57.20) |
| Upside | -2075.4% - -2578.2% | -2258.3% |
| Date | P/E |